Drugs / YZJ-4729
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06681493 | Oct 2022 → Apr 2023 | — | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06901830 | May → Dec 2025 | — | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06680466 | Dec 2023 → Jul 2024 | — | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06890533 | May 2025 → Apr 2026 overdue | — | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YZJ-4729 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06681493 ↗ |
| Known as | YZJ-4729 tartrate | “To evaluate the safety, tolerability, and pharmacokinetic profile of a single dose of YZJ-4729 tartrate injection.” NCT06681493 ↗ |
| Route | Intravenous | “IV YZJ-4729 Tartrate Injection” NCT06890533 ↗ |